{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:39:43Z","timestamp":1793147983077,"version":"4.5.0"},"reference-count":44,"publisher":"Wiley","issue":"4","license":[{"start":{"date-parts":[[2012,2,13]],"date-time":"2012-02-13T00:00:00Z","timestamp":1329091200000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/onlinelibrary.wiley.com\/termsAndConditions#vor"}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Clinical Respiratory J"],"published-print":{"date-parts":[[2012,10]]},"abstract":"<jats:title>Abstract<\/jats:title>\n                  <jats:p>\n                    <jats:bold>Background:\u2002<\/jats:bold>\n                    Tumour necrosis factor\u2010alpha (TNF\u2010\u03b1) plays a crucial role in sarcoidosis. In severe disease, treatment with TNF\u2010\u03b1 inhibitors may be effective.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Objectives:\u2002<\/jats:bold>\n                    Changes in sarcoid disease activity were assessed by fluorine\u201018\u2010fluorodeoxyglucose positron emission tomography (FDG\u2010PET) in patients with recalcitrant sarcoidosis treated with adalimumab.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Methods:\u2002<\/jats:bold>\n                    Prospective 24\u2010week observational study. Patients continued medication with steroids and antimetabolites and received adalimumab 40\u2003mg subcutaneously every other week. Ten patients with biopsy\u2010proven sarcoidosis (two men) were included with a median age of 47 years (range 35\u201373). An FDG\u2010PET showing uptake indicating sarcoid activity was required at inclusion and repeated at the end of the study. FDG\u2010PET uptake was assessed by calculated standardised uptake value (SUV). Blood samples and lung function tests were performed regularly. Quality of life was assessed by the short\u2010form health survey (SF\u201036) questionnaire.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Results:\u2002<\/jats:bold>\n                    Following treatment with adalimumab, FDG\u2010PET uptake decreased in nine patients (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.011) and increased in one patient. Maximum SUV fell from median 14.1 to 7.0 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030.03), and mean SUV fell from median 6.5 to 2.9 (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003&lt;\u20030.02). Six patients had uptake in the lungs, which decreased after treatment (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.035). Six patients had uptake in the lymph nodes, which decreased after treatment in five patients (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.035). Four patients had non\u2010lymphatic extrathoracic uptake, which decreased after treatment (\n                    <jats:italic>P<\/jats:italic>\n                    \u2003=\u20030.05). There was no effect of adalimumab on pulmonary function tests, serum angiotensin I converting enzyme and blood lymphocyte (CD3+, CD4+, CD8+) concentrations. Physical component summary score (SF\u201036) increased during treatment, mental component summary score was unchanged.\n                  <\/jats:p>\n                  <jats:p>\n                    <jats:bold>Conclusion:\u2002<\/jats:bold>\n                    In sarcoidosis, treatment with adalimumab can reduce disease activity, as assessed by FDG\u2010PET.\n                  <\/jats:p>\n                  <jats:p>\n                    Please cite this paper as: Milman N, Graudal N, Loft A, Mortensen J, Larsen J and Baslund B. Effect of the TNF\u2010\u03b1 inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG\u2010PET.\n                    <jats:italic>Clin Respir J<\/jats:italic>\n                    2012; DOI:10.1111\/j.1752\u2010699X.2011.00276.x.\n                  <\/jats:p>","DOI":"10.1111\/j.1752-699x.2011.00276.x","type":"journal-article","created":{"date-parts":[[2011,12,1]],"date-time":"2011-12-01T17:32:04Z","timestamp":1322760724000},"page":"238-247","source":"Crossref","is-referenced-by-count":63,"title":["Effect of the TNF\u2010\u03b1 inhibitor adalimumab in patients with recalcitrant sarcoidosis: a prospective observational study using FDG\u2010PET"],"prefix":"10.1111","volume":"6","author":[{"given":"Nils","family":"Milman","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Niels","family":"Graudal","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Annika","family":"Loft","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jann","family":"Mortensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Janni","family":"Larsen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Bo","family":"Baslund","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"311","published-online":{"date-parts":[[2012,2,13]]},"reference":[{"key":"e_1_2_7_2_2","doi-asserted-by":"publisher","DOI":"10.1164\/ajrccm.160.2.ats4-99"},{"key":"e_1_2_7_3_2","first-page":"46","article-title":"Sarcoidosis in Denmark 1980\u20131994. A registry\u2010based incidence study comprising 5536 patients","volume":"20","author":"Byg K\u2010E","year":"2003","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_2_7_4_2","first-page":"1","article-title":"Is there a role for microorganisms in the pathogenesis of sarcoidosis?","volume":"253","author":"Du Bois RM","year":"2001","journal-title":"J Int Med"},{"key":"e_1_2_7_5_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.04.012"},{"key":"e_1_2_7_6_2","doi-asserted-by":"publisher","DOI":"10.1159\/000090991"},{"key":"e_1_2_7_7_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.00002607"},{"key":"e_1_2_7_8_2","first-page":"50","article-title":"Pulmonary sarcoidosis in the Nordic countries 1950\u20131982. Epidemiology and clinical picture","volume":"7","author":"Milman N","year":"1990","journal-title":"Sarcoidosis"},{"key":"e_1_2_7_9_2","first-page":"113","article-title":"Pulmonary sarcoidosis in the Nordic countries 1950\u20131982. II. Course and prognosis","volume":"7","author":"Milman N","year":"1990","journal-title":"Sarcoidosis"},{"key":"e_1_2_7_10_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01075.x"},{"key":"e_1_2_7_11_2","first-page":"60","article-title":"Methotrexate is steroid sparing in acute sarcoidosis: results of a double blind, randomized trial","volume":"17","author":"Baughman RP","year":"2000","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_2_7_12_2","doi-asserted-by":"publisher","DOI":"10.1046\/j.1365-2796.2003.01076.x"},{"key":"e_1_2_7_13_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.99.14511179"},{"key":"e_1_2_7_14_2","doi-asserted-by":"publisher","DOI":"10.1517\/14728220903449244"},{"key":"e_1_2_7_15_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00010403"},{"key":"e_1_2_7_16_2","doi-asserted-by":"publisher","DOI":"10.1183\/09031936.03.00083002"},{"key":"e_1_2_7_17_2","first-page":"185","article-title":"Exaggerated TNF\u03b1 release of alveolar macrophages in corticosteroid resistant sarcoidosis","volume":"19","author":"Ziegenhagen MW","year":"2002","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_2_7_18_2","first-page":"143","article-title":"18F\u2010FDG PET in sarcoidosis: an observational study in 12 patients treated with infliximab","volume":"25","author":"Keijsers RG","year":"2008","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_2_7_19_2","first-page":"70","article-title":"Infliximab for refractory sarcoidosis","volume":"18","author":"Baughmann RP","year":"2001","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_2_7_20_2","first-page":"484","article-title":"Treatment of severe sarcoidosis using TNF\u2010alpha\u2010inhibitor (infliximab) (article in Danish)","volume":"168","author":"Milman N","year":"2006","journal-title":"Ugeskr Laeger"},{"key":"e_1_2_7_21_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1752-699X.2007.00023.x"},{"key":"e_1_2_7_22_2","doi-asserted-by":"publisher","DOI":"10.1164\/rccm.200603-402OC"},{"key":"e_1_2_7_23_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1365-2230.2010.03829.x"},{"key":"e_1_2_7_24_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-011-1968-x"},{"key":"e_1_2_7_25_2","doi-asserted-by":"publisher","DOI":"10.4076\/1752-1947-3-8573"},{"key":"e_1_2_7_26_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00415-009-0077-1"},{"key":"e_1_2_7_27_2","first-page":"1650","article-title":"Is there a role for FDG PET imaging in the management of patients with sarcoidosis?","volume":"35","author":"Alavi A","year":"1994","journal-title":"J Nucl Med"},{"key":"e_1_2_7_28_2","first-page":"1653","article-title":"Cancer or inflammation? A Holy Grail for nuclear medicine","volume":"35","author":"Larson SM","year":"1994","journal-title":"J Nucl Med"},{"key":"e_1_2_7_29_2","doi-asserted-by":"publisher","DOI":"10.1159\/000072906"},{"key":"e_1_2_7_30_2","doi-asserted-by":"publisher","DOI":"10.1097\/RLU.0b013e3181b53155"},{"key":"e_1_2_7_31_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00259-009-1376-6"},{"key":"e_1_2_7_32_2","first-page":"66","article-title":"Imaging the inflammatory activity of sarcoidosis: sensitivity and inter observer agreement of (67)Ga imaging and (18)F\u2010FDG PET","volume":"55","author":"Keijsers RG","year":"2011","journal-title":"Q J Nucl Med Mol Imaging"},{"key":"e_1_2_7_33_2","doi-asserted-by":"crossref","first-page":"163","DOI":"10.1093\/clinchem\/30.1.163","article-title":"Single reagent microcentrifugal assay for angiotensin converting enzyme in serum","volume":"30","author":"Neels HM","year":"1984","journal-title":"Clin Chem"},{"key":"e_1_2_7_34_2","unstructured":"Bj\u00f8rnerJB DamsgaardMT WattT BechP RasmussenNK KristensenTS ModvigJ ThunedborgK.Danish manual to SF\u201036. A questionnaire about health status. Copenhagen1997: L\u00e6gemiddelindustriforeningen."},{"key":"e_1_2_7_35_2","unstructured":"National Institute for Health and Clinical Excellence.Infliximab (review) and adalimumab for treatment of Crohn's disease. NICE technology appraisal guidance 187.2011. Available at:http:\/\/www.nice.org.uk\/guidance\/TA187(accessed 14 Dec 2011)."},{"key":"e_1_2_7_36_2","unstructured":"National Institute for Health and Clinical Excellence.Adalimumab eternacept and infliximab for the treatment of rheumatoid arthritis. NICE technology appraisal guidance 130.2007. Available at:http:\/\/www.nice.org.uk\/TA130(accessed 14 Dec 2011)."},{"key":"e_1_2_7_37_2","first-page":"76","article-title":"Inhibitors of tumor necrosis factor (TNF) in sarcoidosis: who, what, and how to use them","volume":"25","author":"Baughman RP","year":"2008","journal-title":"Sarcoidosis Vasc Diffuse Lung Dis"},{"key":"e_1_2_7_38_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.rmed.2008.12.007"},{"key":"e_1_2_7_39_2","doi-asserted-by":"publisher","DOI":"10.1159\/000314225"},{"key":"e_1_2_7_40_2","unstructured":"Summary of Product Characteristics European Medicines Agency.Humira Summary of Product Characteristics.European Medicines Agency. Available at:http:\/\/www.ema.europa.eu\/docs\/en_GB\/document_library\/EPAR_-_Product_Information\/human\/000481\/WC500050870.pdf(accessed 14 Dec 2011)."},{"key":"e_1_2_7_41_2","doi-asserted-by":"publisher","DOI":"10.2515\/therapie\/2011014"},{"key":"e_1_2_7_42_2","doi-asserted-by":"publisher","DOI":"10.1159\/000275676"},{"key":"e_1_2_7_43_2","doi-asserted-by":"publisher","DOI":"10.1016\/j.semarthrit.2008.11.003"},{"key":"e_1_2_7_44_2","doi-asserted-by":"publisher","DOI":"10.1007\/s00296-008-0691-8"},{"key":"e_1_2_7_45_2","doi-asserted-by":"publisher","DOI":"10.1111\/j.1440-0960.2010.00660.x"}],"container-title":["The Clinical Respiratory Journal"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.wiley.com\/onlinelibrary\/tdm\/v1\/articles\/10.1111%2Fj.1752-699X.2011.00276.x","content-type":"unspecified","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/pdf\/10.1111\/j.1752-699X.2011.00276.x","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2023,10,31]],"date-time":"2023-10-31T00:36:02Z","timestamp":1698712562000},"score":1,"resource":{"primary":{"URL":"https:\/\/onlinelibrary.wiley.com\/doi\/10.1111\/j.1752-699X.2011.00276.x"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2012,2,13]]},"references-count":44,"journal-issue":{"issue":"4","published-print":{"date-parts":[[2012,10]]}},"alternative-id":["10.1111\/j.1752-699X.2011.00276.x"],"URL":"https:\/\/doi.org\/10.1111\/j.1752-699x.2011.00276.x","archive":["Portico"],"relation":{},"ISSN":["1752-6981","1752-699X"],"issn-type":[{"value":"1752-6981","type":"print"},{"value":"1752-699X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2012,2,13]]}}}